I-Mab (NASDAQ:IMAB) and Vincerx Pharma (NASDAQ:VINC) Head-To-Head Survey

I-Mab (NASDAQ:IMAB) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings.

Earnings and Valuation

This table compares I-Mab and Vincerx Pharma’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$27.64 million	3.42	-$206.44 million	N/A	N/A
Vincerx Pharma	N/A	N/A	-$40.16 million	($1.79)	-0.44

Vincerx Pharma has lower revenue, but higher earnings than I-Mab.

Institutional & Insider Ownership

38.4% of I-Mab shares are held by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are held by institutional investors. 22.1% of I-Mab shares are held by company insiders. Comparatively, 22.9% of Vincerx Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for I-Mab and Vincerx Pharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	0	0	4	0	3.00
Vincerx Pharma	0	0	1	0	3.00

I-Mab currently has a consensus price target of $12.25, suggesting a potential upside of 947.01%. Vincerx Pharma has a consensus price target of $5.00, suggesting a potential upside of 532.91%. Given I-Mab’s higher probable upside, analysts clearly believe I-Mab is more favorable than Vincerx Pharma.

Risk and Volatility

I-Mab has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Vincerx Pharma has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.

Profitability

This table compares I-Mab and Vincerx Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Vincerx Pharma	N/A	-261.83%	-145.47%

Summary

I-Mab beats Vincerx Pharma on 5 of the 9 factors compared between the two stocks.

About I-Mab

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

About Vincerx Pharma

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.